The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Abstract
Antibodies targeting checkpoint inhibitors or co‐stimulatory receptors on T cells have shown significant antitumor efficacy in preclinical and clinical studies. In mouse tumor models, engagement of activating Fcγ receptor (FcγR)‐expressing immune cells was recently shown to be required for the tumoricidal activity of antibodies recognizing the tumor necrosis factor superfamily receptor (TNFR) GITR (CD357) and CTLA‐4 (CD152). In particular, activating FcγRs facilitated the selective elimination of intratumoral T‐cell populations. However, it remains unclear whether FcγRs contribute to the antitumor efficacy of other immunomodulatory antibodies. Here, we explored the mechanism of antitumor activity mediated by an agonistic antibody (clone OX86) to the co‐stimulatory TNFR OX40 (CD134). OX40 was highly expressed by intratumoral T cells, particularly those of the FoxP3+ regulatory T‐cell (Treg) lineage. OX86 administration resulted in the depletion of intratumoral regulatory T cells in an activating FcγR‐dependent manner, which correlated with tumor regression. Together with previous data from our group and others, these findings support a mechanism whereby antibodies targeting antigens highly expressed by intratumoral T cells can mediate their elimination by FcγR‐expressing immune cells, and facilitate subsequent antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Self-citationFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Fcγ Receptors: Old Friends and New Family Members
Nimmerjahn, F., & Ravetch, J. V. (2006) · Immunity · doi:10.1016/j.immuni.2005.11.010 · Cited by 1,072
Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857
Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells
Turk, M. J., Guevara-Patiño, J. A., Rizzuto, G. A., Engelhorn, M. E., & Houghton, A. N. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041130 · Cited by 540
Ox-40 Ligand: A Potent Costimulatory Molecule for Sustaining Primary CD4 T Cell Responses
Gramaglia, I., Weinberg, A. D., Lemon, M., & Croft, M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.12.6510 · Cited by 527
Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., & Sakaguchi, S. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050940 · Cited by 466
Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., & Sakaguchi, S. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.200509402092c · Cited by 462
Cited by
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
Resistance to PD1/PDL1 checkpoint inhibition
O'Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. L., & Smyth, M. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.007 · Cited by 572
Roles of regulatory T cells in cancer immunity
Takeuchi, Y., & Nishikawa, H. (2016) · International Immunology · doi:10.1093/intimm/dxw025 · Cited by 523
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Melero, I., Castanon, E., Alvarez, M., Champiat, S., & Marabelle, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00507-y · Cited by 493
Reversing T-cell Dysfunction and Exhaustion in Cancer
Zarour, H. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1849 · Cited by 462
Targeting Treg cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2019) · European Journal of Immunology · doi:10.1002/eji.201847659 · Cited by 476
Arce Vargas, F., Furness, A. J. S., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M. H., Miranda Rota, E., Dahan, R., Georgiou, A., Sledzinska, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.013 · Cited by 418
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Dahan, R., Sega, E., Engelhardt, J., Selby, M., Korman, A. J., & Ravetch, J. V. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.004 · Cited by 409
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
Young, A., Ngiow, S. F., Barkauskas, D. S., Sult, E., Hay, C., Blake, S. J., Huang, Q., Liu, J., Takeda, K., Teng, M. W. L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.025 · Cited by 388
Eradication of spontaneous malignancy by local immunotherapy
Sagiv-Barfi, I., Czerwinski, D. K., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., & Levy, R. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4488 · Cited by 361
The promise and challenges of immune agonist antibody development in cancer
Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 355
T Cell Dysfunction in Cancer Immunity and Immunotherapy
Xia, A., Zhang, Y., Xu, J., Yin, T., & Lu, X.-J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 341
Rationale for anti-OX40 cancer immunotherapy
Aspeslagh, S., Postel-Vinay, S., Rusakiewicz, S., Soria, J.-C., Zitvogel, L., & Marabelle, A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.021 · Cited by 318
The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy
Buchan, S. L., Rogel, A., & Al-Shamkhani, A. (2018) · Blood · doi:10.1182/blood-2017-07-741025 · Cited by 276
Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity
Fu, Y., Lin, Q., Zhang, Z., & Zhang, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.010 · Cited by 260
Guttman-Yassky, E., Pavel, A. B., Zhou, L., Estrada, Y. D., Zhang, N., Xu, H., Peng, X., Wen, H.-C., Govas, P., Gudi, G., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.053 · Cited by 220
Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812186116 · Cited by 205
Gaspar, M., Pravin, J., Rodrigues, L., Uhlenbroich, S., Everett, K. L., Wollerton, F., Morrow, M., Tuna, M., & Brewis, N. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0798 · Cited by 58
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy
Cohen Saban, N., Yalin, A., Landsberger, T., Salomon, R., Alva, A., Feferman, T., Amit, I., & Dahan, R. (2023) · Science Immunology · doi:10.1126/sciimmunol.add8005 · Cited by 39
Metadata
- Authors
- Bulliard, Y., Jolicoeur, R., Zhang, J., Dranoff, G., Wilson, N. S., & Brogdon, J. L.
- Venue
- Immunology & Cell Biology
- Publisher
- Wiley
- Published
- 2014-04-15
- Volume
- 92
- Issue
- 6
- Pages
- 475-480
- ISSN
- 0004-945X (ISSN-L)
- 0818-9641
- 1440-1711
- OpenAlex
- W2071875829
- Cited by
- 284
- References
- 34
- FWCI
- 13.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.